On Monday, September 14, 2015 Stemcell United Limited (ASX:SCU) (formerly On Q Group Limited) successfully relisted on the ASX.

Stemcell United is a biotechnology company focused on using stem cell technology to grow, reproduce, culture and extract plant cells for use in Traditional Chinese Medicine. This follows the company’s successful capital raise, which will enable Stemcell United to expand its sales and distribution, and commercialise its proprietary stem cell technology.

The HLB Corporate Advisory team in Sydney, including Simon James, Nicholas Guest and Charlotte Sandell, produced the Independent Expert’s Report in relation to the On Q Group and Stemcell United transaction. Our work in this assignment involved the valuation of shares and of the consideration provided, and our report accompanied the Notice of Meeting materials provided to shareholders.

The partners and senior staff forming the HLB team possess sound business acumen and significant expertise. Our commercial experience combined with our technical skills ensures our clients are provided with valuable, timely and expert advice, that adds value whilst reducing risk.

HLB Mann Judd’s Corporate Advisory team has considerable experience in capital market transactions, including assisting businesses prepare for an IPO, preparation of Investigating Accountants Reports to accompany capital raising offer documentation, and the preparation of Independent Expert Reports in relation to corporate transactions pursuant to Corporations Act requirements and ASX listing rules.